Last reviewed · How we verify
DAHANCA 37. Re-irradiation With Proton Radiotherapy
Summary Design Phase II observational Treatment * 60 Gy/50 fx / 10W-1 at 1.2 Gy/fx o i.e. EQD2 tumor=56 Gy, EQD2 late=50.4 Gy at α/β= 10 and 3, respectively * Proton radiotherapy * Concomitant cisplatin for eligible patients\* * Nimorazole recommended for SCC\* \*The concurrent medical treatment (weekly cisplatin and nimorazole) are prescribed according to the national treatment guidelines, and are not part of the experimental treatment. Endpoints * Primary: o Any new late toxicity grade \>=3 according to CTC AE 5.0 * Secondary * Side effects according to DAHANCA scoring system * Quality of life and PROM according to EORTC C30 and HN43 * Loco-regional control (LRC) * Overall survival (OS)
Details
| Lead sponsor | Danish Head and Neck Cancer Group |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 20 |
| Start date | Sun Sep 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Aug 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Head and Neck Neoplasms
Interventions
- Re-irradiation
Countries
Denmark